The thousands of microbial species that compose the human gut microbiome are linked to diseases from cancer to diabetes, sparking tremendous interest among pharmaceutical/ medical researchers in microbiome analytics. Current analytics methods are far too slow, expensive, and inaccurate to fulfil this need. Much faster techniques are essential for microbiome tracking over the course of disease states and therapies to discover correlations with disease and enable personalized medicine. Perseus MAP is the only microbiome analytics platform that will be able to handle this onslaught of demand, through a revolutionarily fast, high-throughput, and accurate technology based on DNA imaging techniques invented in the lab of our co-founders. We will massively accelerate microbiomics, starting with a central service lab, deploying satellite labs, and finally producing portable units for the microbiomics mass market, at a capacity of 300k profiles/yr analyzed in-house to seize a €2.5B market.

280M of people worldwide suffers from major depressive disorders (MDD). Although a well-populated therapeutic landscape of anti-depre280M of people worldwide suffers from major depressive disorders (MDD). Although a well-populated therapeutic landscape of anti-depressants, the number of patients in remission is particularly low with not more than 6% of the patients who benefit from the current therapeutic journey. OPADE objective is to identify key biomarkers that support the decision-making process of the healthcare providers. The project focuses on the microbiota – brain -axis which plays a major role in mental health and in particular MDD. Through clinical investigations, the consortium partners will study the combination between genetics, epigenetics, microbiome and inflammatory networks to: - Establish patient profiles to predict and optimise the efficacy of the antidepressants prescribed with an increase in the remission rate and reduction of impairment of real-life functioning, - Establish the possible correlation between neuroinflammatory indices, target indicators of the microbiome, metabolomics, immune-profile linked, epigenomic, enzymatic algorithms, - Evaluate molecular and non-molecular biomarkers that may represent predictive indices of recurrence - Discover new molecular targets for a personalised approach, - Improve the diagnostic accuracy for primary prevention, - Evaluate retrospectively, using accurate anamnesis, the onset of depressive symptoms in adolescence. - Establish how much and to what extent do blood biomarkers correlate with other specific biomarkers 350 patients between 14 and 50 years will be recruited in 6 EU and international countries for 24 months. Real-time EEG and patient cognitive assessment will be collected with blood, stool and saliva samples. Results and analysis will be used to train the AI / ML predictive tool, the main outcome of the project. A patient empowerment tool will be deployed over the project duration.